Information de reference pour ce titreAccession Number: | 01217111-200911000-00002.
|
Author: | Gillings, Annette S.; Balmanno, Kathryn; Wiggins, Ceri M.; Johnson, Mark; Cook, Simon J.
|
Institution: | Laboratory of Molecular Signalling, The Babraham Institute, Babraham Research Campus, Cambridge, UK
|
Title: | |
Source: | FEBS Journal. 276(21):6050-6062, November 2009.
|
Abstract: | : The BCL-2 homology domain 3 (BH3)-only protein, B-cell lymphoma 2 interacting mediator of cell death (BIM) is a potent pro-apoptotic protein belonging to the B-cell lymphoma 2 protein family. In recent years, advances in basic biology have provided a clearer picture of how BIM kills cells and how BIM expression and activity are repressed by growth factor signalling pathways, especially the extracellular signal-regulated kinase 1/2 and protein kinase B pathways. In tumour cells these oncogene-regulated pathways are used to counter the effects of BIM, thereby promoting tumour cell survival. In parallel, a new generation of targeted therapeutics has been developed, which show remarkable specificity and efficacy in tumour cells that are addicted to particular oncogenes. It is now apparent that the expression and activation of BIM is a common response to these new therapeutics. Indeed, BIM has emerged from this marriage of basic and applied biology as an important mediator of tumour cell death in response to such drugs. The induction of BIM alone may not be sufficient for significant tumour cell death, as BIM is more likely to act in concert with other BH3-only proteins, or other death pathways, when new targeted therapeutics are used in combination with traditional chemotherapy agents. Here we discuss recent advances in understanding BIM regulation and review the role of BIM as a mediator of tumour cell death in response to novel oncogene-targeted therapeutics.
Copyright (C) 2009 Blackwell Publishing Ltd.
|
Author Keywords: | B-cell lymphoma 2 (BCL-2); breakpoint cluster region/Abelson murine leukaemia viral oncogene (BCR/ABL); BCL-2-interacting mediator of cell death (BIM); v-raf murine sarcoma viral oncogene homologue B1 (BRAF); epidermal growth factor receptor (EGFR); extracellular signal-regulated kinase 1/2 (ERK1/2); mitogen-MAPK or ERK Kinase 1/2 (MEK1/2); protein kinase B (PKB); ribosomal protein S6 kinase (RSK).
|
References: | 1 Adams J & Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26, 1324-1337.
2 Youle RJ & Strassser A (2009) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9, 47-59.
3 Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Lerino H, Lee EF, Fairlie WD, Bouillet P et al. (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315, 856-859.
4 Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM & Huang DC (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17, 393-403.
5 O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S & Huang DC (1998) Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 17, 384-395.
6 U M, Miyashita T, Shikama Y, Tadokoro K & Yamada M (2001) Molecular cloning and characterization of six novel isoforms of human Bim, a member of the proapoptotic Bcl-2 family. FEBS Lett 509, 135-141.
7 Ley R, Ewings KE, Hadfield K & Cook SJ (2005) Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ 12, 1008-1014.
8 Lei K & Davis RJ (2003) JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 100, 2432-2437.
9 Hubner A, Barrett T, Flavell RA & Davis RJ (2008) Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell 30, 415-425.
10 Balmanno K & Cook SJ (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16, 368-377.
11 Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5, 876-885.
12 Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, Adams JM & Strasser A (1999) Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286, 1735-1738.
13 Whitfield J, Neame SJ, Paquet L, Bernard O & Ham J (2001) Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 29, 629-643.
14 Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R, Degenhardt K, White E & Cook SJ (2007) ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J 26, 2856-2867.
15 Gilley J, Coffer PJ & Ham J (2003) FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 162, 613-622.
16 Fu Z & Tindall DJ (2007) FOXOs, cancer and regulation of apoptosis. Oncogene 27, 2312-2319.
17 Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC et al. (2008) ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10, 138-148.
18 Weston CR, Balmanno K, Chalmers C, Hadfield K, Molton SA, Ley R, Wagner EF & Cook SJ (2003) Activation of ERK1/2 by [DELTA]Raf-1:ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene 22, 1281-1293.
19 Ley R, Balmanno K, Hadfield K, Weston C & Cook SJ (2003) Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278, 18811-18816.
20 Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G & Auberger P (2003) Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22, 6785-6793.
21 Marani M, Hancock D, Lopes R, Tenev T, Downward J & Lemoine NR (2004) Role of Bim in the survival pathway induced by Raf in epithelial cells. Oncogene 23, 2431-2441.
22 Ewings KE, Wiggins CM & Cook SJ (2007) Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels. Cell Cycle 6, 2236-2240.
23 Akiyama T, Bouillet P, Miyazaki T, Kadono Y, Chikuda H, Chung UI, Fukuda A, Hikita A, Seto H, Okada T et al. (2003) Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J 22, 6653-6664.
24 El Chami N, Ikhlef F, Kaszas K, Yakoub S, Tabone E, Siddeek B, Cunha S, Beaudoin C, Morel L, Benahmed M et al. (2005) Androgen-dependent apoptosis in male germ cells is regulated through the proto-oncoprotein Cbl. J Cell Biol 171, 651-661.
25 Wiggins CM, Band H & Cook SJ (2007) c-Cbl is not required for ERK1/2-dependent degradation of BimEL. Cell Signal 19, 2605-2611.
26 Zhang W, Cheng GZ, Gong J, Hermanto U, Zong CS, Chan J, Cheng JQ & Wang LH (2008) RACK1 and CIS mediate the degradation of BimEL in cancer cells. J Biol Chem 283, 16416-16426.
27 Dehan E, Bassermann F, Guardavaccaro D, Vasiliver-Shamis G, Cohen M, Lowes KN, Dustin M, Huang DC, Taunton J & Pagano M (2009) [beta]TrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell 33, 109-116.
28 Ley R, Ewings KE, Hadfield K, Howes E, Balmanno K & Cook SJ (2004) Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem 279, 8837-8847.
29 Ley R, Hadfield K, Howes E & Cook SJ (2005) Identification of a DEF-type docking domain for extracellular signal-regulated kinases 1/2 that directs phosphorylation and turnover of the BH3-only protein BimEL. J Biol Chem 280, 17657-17663.
30 Haber DA & Settleman J (2007) Cancer: drivers and passengers. Nature 446, 145-146.
31 Hanahan D & Weinberg RA (2000) The hallmarks of cancer. Cell 100, 57-70.
32 Weinstein IB & Joe A (2008) Oncogene addiction. Cancer Res 68, 3077-3080.
33 Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49, 4682-4689.
34 Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
35 Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C et al. (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11, 1192-1197.
36 Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S et al. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5, 810-816.
37 Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J et al. (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23, 5281-5293.
38 Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP et al. (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22, 4456-4462.
39 Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362.
40 Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S & Smith PD (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6, 2209-2219.
41 Wickenden JA, Jin H, Johnson M, Gillings AS, Newson C, Austin M, Chell SD, Balmanno K, Pritchard CA & Cook SJ (2008) Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene 27, 7150-7161.
42 Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ & McMahon M (2008) Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res 21, 534-544.
43 Cragg MS, Jansen ES, Cook M, Harris C, Strasser A & Scott CL (2008) Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 118, 3651-3659.
44 Boisvert-Adamo K & Aplin AE (2008) Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene 27, 3301-3312.
45 Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD & Hersey P (2007) Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res 13, 4934-4942.
46 Sheridan C, Brumatti G & Martin SJ (2008) Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim. J Biol Chem 283, 22128-22135.
47 Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, Minjian JY, DePinho RA, McMahon M & Bosenberg M (2009) BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41, 544-552.
48 Balmanno K, Chell SD, Gillings AS, Hayat S & Cook SJ (2009) Intrinsic resistamnce to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 125, 2332-2341.
49 Dai Y, Yu C, Singh V, Tang L, Wang Z, McInistry R, Dent P & Grant S (2001) Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 61, 5106-5115.
50 Pei XY, Dai Y, Tenorio S, Lu J, Harada H, Dent P & Grant S (2007) MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Blood 110, 2092-2101.
51 Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139.
52 Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X & Pao W (2007) Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 4, e294.
53 Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG & Kobayashi S (2007) BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 4, 1669-1679.
54 Cragg MS, Kuroda J, Puthalakath H, Huang DC & Strasser A (2007) Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 4, 1681-1689.
55 Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, Wong KK & Letai A (2007) Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 67, 11867-11875.
56 Deininger MWN, Goldman JM & Melo JV (2000) The molecular biology of chronic myeloid leukaemia. Blood 96, 3343-3356.
57 Maekawa T, Ashihara E & Kimura S (2007) The Bcr/Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukaemias. Int J Clin Oncol 12, 327-340.
58 Druker BJ (2002) Inhibition of the Brc-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 21, 8541-8546.
59 Nimmanapalli R & Bhalla K (2002) Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. Oncogene 21, 8584-8590.
60 Zhang J, Yang PL & Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9, 28-39.
61 Shinjyo T, Kuribara R, Inukai T, Hosoi H, Kinoshita T, Miyajima A, Houghton PJ, Look AT, Ozawa K & Inaba T (2001) Downregulation of Bim, a proapoptotic relative of Bcl-2, is the pivotal step in cytokine-initiated survival signalling in murine hematopoietic progenitors. Mol Cell Biol 2, 854-864.
62 Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, Sugita K, Nakazawa S, Hirai H, Ozawa K & Inaba T (2009) Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoeitic progentors. Mol Cell Biol 24, 6172-6183.
63 Aichberger KJ, Mayerhofer M & Krauth MT (2005) Low level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukaemia: role of Bcr/Abl, characterisation of underlying signalling pathways and re-expression by novel pharmacologic compounds. Cancer Res 65, 9436-9444.
64 Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DCS, Kimura S, Ottmann OG, Druker BJ, Villunger A et al. (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103, 14907-14912.
65 Belloc F, Moreau-Gaudry F, Uhalde M, Cazalis L, Jeanneteau M, Lacombe F, Praloran V & Mahon F-X (2007) Imatinib and nilotinib induce apoptosis of chronic myeloid leukaemia cells through a Bim dependent pathway modulated by cytokines. Cancer Biol Ther 6, 912-919.
66 Kuroda J, Kimura S, Strasser A, Andreef A, O'Reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M et al. (2007) Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr/Abl inhibitor, and ABT-737, and inhibitor of antiapoptotic Bcl-2 proteins, against Bcr/Abl-positive leukaemia. Cell Death Differ 14, 1667-1677.
67 Dai Y, Chen S, Venditti CA, Pei X-Y, Nguyen TK, Dent P & Grant S (2008) Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukaemia cells sensitive and resistant to imatinib mesylate. Blood 112, 793-804.
68 Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P & Grant S (2002) Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukaemia cells. Cancer Res 62, 188-199.
69 Nguyen TK, Rahmani M, Harada H, Dent P & Grant S (2007) MEK1/2 inhibitors sensitize Bcr/Abl+ human leukaemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 109, 4006-4015.
70 Nordigarden A, Kraft M, Eliasson P, Labi V, Lam EWF, Villunger A & Jonsson J-I (2009) BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. Blood 113, 2302-2311.
71 Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C et al. (2008) Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 118, 3051-3064.
72 Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL & Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22, 159-168.
73 Lowe SW, Cepero E & Evan GI (2004) Intrinsic tumour suppression. Nature 432, 307-315.
74 Egle A, Harris AW, Bouillet P & Cory S (2004) Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 101, 6164-6169.
75 Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee J et al. (2008) Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 68, 6643-6651.
76 Vogler M, Dinsdale D, Dyer MJS & Cohen GM (2009) Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 16, 360-367.
77 Cragg MS, Harris C, Strasser A & Scott CL (2009) Unleashing the power of oncogenic kinase inhibitors through BH3-mimetics. Nat Rev Cancer 9, 321-326.
78 Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON & Green DR (1998) Bcl-2-independent Bcr/Abl mediated resistance to apoptosis: protection is correlated with upregulation of Bcl-XL. Oncogene 16, 1383-1390.
79 Ravandi F, Kantajian HM, Talpaz M, O'Brien S, Giles FJ, Cortes TD, Andreeff M, Estrov Z, Rios MB & Albitar M (2001) Expression of apoptosis proteins in chronic myelogenouse leukaemia: associations and significance. Cancer 91, 1964-1972.
|
Language: | English.
|
Document Type: | Minireview.
|
Journal Subset: | Life Sciences.
|
ISSN: | 1742-464X
|
NLM Journal Code: | 101229646
|
DOI Number: | https://dx.doi.org/10.1111/j.174...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|